Eruptive angiolipomas associated with antiretroviral therapy.
Eruptive angiolipomas associated with antiretroviral therapy.
复制标题
与抗逆转录病毒治疗相关的爆发性血管脂肪瘤。
DOI：
10.1097/00002030-200203290-00024
复制
发表时间：
2002
期刊：
影响因子：
3.8
通讯作者：
A. García‐Díez
中科院分区：
文献类型：
--
作者：
E. Daudén;S. Álvarez;A. García‐Díez
有效的新型抗逆转录病毒药物，特别是蛋白酶抑制剂的引入，对艾滋病毒感染者的发病率和生存产生了重要影响。然而，越来越多的与这些方案相关的并发症已被认识到。最近，有报道称，在开始使用抗逆转录病毒疗法（包括茚地那韦）治疗后不久就会出现皮下脂肪瘤和血管脂肪瘤[1, 2]。我们想报告一名 HIV 阳性患者，她出现发疹性血管脂肪瘤，可能是由沙奎那韦引起。一名 49 岁的女性，自 1993 年起 HIV 呈阳性，于 1999 年 3 月就诊于我们科室。她提到 5 年前，右大腿出现一个皮下结节，第二年左大腿出现一个新结节。此后，病变一直保持稳定。就诊前八个月，她注意到右臀部和双大腿上突然出现了六个稍有压痛的结节，并且先前病变的尺寸同时增大。这些变化与身体脂肪的逐渐重新分配同时发生。该患者自 1996 年以来一直接受齐多夫定、扎西他滨和去羟肌苷治疗。由于治疗无效，在上述结节和皮下脂肪发生变化前3个月开始使用司他夫定（30 mg，每天两次）、拉米夫定（150 mg，每天两次）和蛋白酶抑制剂沙奎那韦（600 mg，每8小时）的新方案。
The introduction of potent new antiretroviral drugs, particularly protease inhibitors, has had an important impact on morbidity and survival in HIV-infected individuals. However, an increasing number of complications associated with these regimens have been recognized. Recently, the appearance of subcutaneous lipomas and angiolipomas shortly after starting treatment with antiretroviral therapy, including indinavir, has been described [1, 2]. We would like to report on one HIV-positive patient who presented with eruptive angiolipomas, probably induced by saquinavir.A 49-year-old woman, HIV-positive since 1993, presented at our department in March 1999. She referred to the appearance, 5 years before, of a subcutaneous nodule on the right thigh, and a new nodule on the left thigh the following year. Since then, the lesions have remained stable. Eight months before the consultation, she had noticed the relatively sudden appearance of six more slightly tender nodules on the right hip and both thighs, and a simultaneous increase in the size of the previous lesions. These changes coincided with a progressive body fat redistribution. The patient had been treated since 1996 with zidovudine, zalcitabine and didanosine. Because of the inefficacy of the therapy, a new regimen with stavudine (30 mg twice a day), lamivudine (150 mg twice a day) and the protease inhibitor saquinavir (600 mg every 8 h) was started 3 months before the previously mentioned changes in the nodules and the subcutaneous fat.